AbbVie Extends Reach Of Regenxbio’s Wet AMD Program
Deal May Indicate Renewed Pharma Appetite For Gene Therapy
The partnership worth up to $1.75bn removes the significant risk of going it alone in a competitive market as Regenxbio awaits late-stage data for its gene therapy.
